Product news from the 04/14/06 News Brief

Share this article:
FDA approved Alkermes and Cephalon’s Vivitrol (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence. The FDA has granted final approval to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application for fexofenadine hydrochloride tablets, 30 mg, 60 mg and 180 mg. Fexofenadine hydrochloride is the generic equivalent of Sanofi-Aventis’ allergy drug Allegra. Dr. Reddy’s said it will begin the commercial marketing of this product immediately. Roche has filed for US approval of an expanded lung cancer indication for its Avastin colorectal cancer drug. Roche said studies show that Avastin is beneficial to patients with nonsquamous non-small-cell lung cancer, which accounts for 87% of all lung cancer cases in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.